BRYN MAWR TRUST Co reduced its stake in Teleflex Incorporated (NYSE:TFX) by 1.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,542 shares of the medical technology company’s stock after selling 409 shares during the quarter. BRYN MAWR TRUST Co’s holdings in Teleflex were worth $10,585,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Atalanta Sosnoff Capital LLC purchased a new stake in shares of Teleflex in the fourth quarter valued at $280,000. Legal & General Group Plc lifted its position in Teleflex by 5.8% during the third quarter. Legal & General Group Plc now owns 90,332 shares of the medical technology company’s stock worth $21,854,000 after buying an additional 4,929 shares during the period. California Public Employees Retirement System lifted its position in Teleflex by 5.3% during the third quarter. California Public Employees Retirement System now owns 102,182 shares of the medical technology company’s stock worth $24,725,000 after buying an additional 5,182 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Teleflex by 1.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 128,651 shares of the medical technology company’s stock worth $31,130,000 after buying an additional 2,050 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its position in Teleflex by 6.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 175,269 shares of the medical technology company’s stock worth $42,410,000 after buying an additional 10,576 shares during the period. Institutional investors and hedge funds own 90.75% of the company’s stock.
Teleflex Incorporated (NYSE:TFX) opened at $262.14 on Tuesday. The company has a market capitalization of $11,927.25, a PE ratio of 80.17, a PEG ratio of 1.96 and a beta of 1.22. The company has a quick ratio of 1.51, a current ratio of 2.33 and a debt-to-equity ratio of 0.89. Teleflex Incorporated has a twelve month low of $191.04 and a twelve month high of $288.78.
Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 22nd. The medical technology company reported $2.44 EPS for the quarter, topping analysts’ consensus estimates of $2.40 by $0.04. The company had revenue of $595.10 million for the quarter, compared to the consensus estimate of $601.17 million. Teleflex had a return on equity of 16.46% and a net margin of 7.11%. The company’s quarterly revenue was up 15.8% compared to the same quarter last year. During the same period last year, the business posted $2.13 EPS. equities research analysts anticipate that Teleflex Incorporated will post 9.67 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 15th. Stockholders of record on Friday, March 2nd were issued a $0.34 dividend. The ex-dividend date of this dividend was Thursday, March 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.52%. Teleflex’s dividend payout ratio (DPR) is 41.59%.
In other news, Director George Babich, Jr. sold 2,500 shares of the stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $268.53, for a total value of $671,325.00. Following the completion of the sale, the director now owns 11,083 shares in the company, valued at $2,976,117.99. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP John Deren sold 1,359 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $255.67, for a total value of $347,455.53. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,259 shares of company stock worth $3,760,536. Company insiders own 2.39% of the company’s stock.
Several research firms recently weighed in on TFX. TheStreet downgraded Teleflex from an “a-” rating to a “c+” rating in a research report on Monday, March 12th. ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. Leerink Swann reduced their target price on Teleflex from $321.00 to $300.00 and set an “outperform” rating on the stock in a research report on Friday, February 23rd. Finally, Stephens reiterated a “buy” rating and set a $300.00 target price on shares of Teleflex in a research report on Thursday, January 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $281.56.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/20/bryn-mawr-trust-co-sells-409-shares-of-teleflex-incorporated-tfx.html.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.